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Introduction
Cardiovascular diseases (CVDs) are the leading cause 
of disability and premature death in the world1. According 
to the Global Burden of Disease Study, 422.7 million peo-
ple were affected with CVD and 17.9 million deaths were 
caused by CVD, accounting for 31% of all-cause deaths in 
the world in 20152. CVDs impose a huge and ever growing 
burden upon the individuals, families, and healthcare sys-
tem, obviously necessitating urgent and effective research 
of atherosclerotic pathophysiology and implementation of 
preventive measures3,4. The main clinical manifestations 
of CVD can be divided into those involving the heart and 
cardiovascular system (coronary/ischemic disease); brain 
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A B S T R A C T
Peripheral artery disease (PAD) is an occlusive disease of extremities, which used to be diagnosed and treated as an 
isolated disease of the limbs or other parts of the body. Nowadays, the role of PAD transcends the affected limb; instead, 
the cardiovascular system must be observed as a whole, with PAD having a prognostic role.  About 200 million people are 
affected by PAD worldwide. The prevalence of PAD is likely to increase steadily in the future due to the global aging of 
the population and the predominantly sedentary lifestyle, along with the expected universal increase in the major PAD 
risk factors such as smoking habit, diabetes mellitus, dyslipidemia and hypertension. Patients with PAD are at a higher 
risk of coronary disease and cardiovascular events in comparison to healthy control subjects. The severity of PAD correlates 
with the development and complications of cardiovascular disease. In PAD patients, percutaneous coronary intervention 
is more demanding, associated with more comorbidities, more complex lesions, and poorer procedural success as compared 
with PAD-free patients. For a year now, the use of antiplatelet therapy with acetylsalicylic acid in combination with low 
(vascular) dose of a direct oral anticoagulant has been recommended for cardiovascular and lower limb protection in PAD 
patients.  In the future, we expect a better understanding of atherosclerotic disease, stronger modulation of systemic in-
flammation, and the discovery of new therapies. In the meantime, it is necessary to identify the risk population and ag-
gressively treat the classic factors – control of blood pressure, glycemia and lipids with antiplatelet and new anticoagulant 
therapy. The goal is to protect the limb and preserve the cardiovascular continuum. The negative consequences of COV-
ID-19 on treatment CVD will be estimated in the following years. 
Key words: cardiovascular disease, peripheral artery disease, atherosclerosis, risk factors, coronary, lower extremity, 
primary prevention
and cerebrovascular system (cerebrovascular disease); 
and lower extremities (occlusive disease of peripheral ar-
teries)5. Most frequently, atherosclerosis underlies all 
these diseases. Atherosclerosis is a progressive condition 
characterized by diseased endothelium, low-grade inflam-
mation, lipid accumulation, and plaque formation within 
the vascular wall intima media6. Plaque rupture or ero-
sion can cause superimposed atherothrombosis and sub-
sequent vascular occlusion, which in turn leads to cardio-
vascular events including myocardial infarction, stroke, 
limb ischemia, and cardiovascular death7. In Europe, 
about 4 million people die from CVD per year, accounting 
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for 45% of all-cause deahs8. More than 42% of coronary 
disease patients also suffer from peripheral artery dis-
ease9. 
Peripheral Artery Disease Definition and 
Diagnosis
Peripheral artery disease (PAD) defines an atheroscle-
rotic stenosis or occlusive disease involving the arteries of 
upper and lower extremities, arteries of the cerebrovascu-
lar system (carotid and vertebral arteries), mesenteric and 
renal arteries, but not including aorta and coronary artery 
disease. Polyvascular disease is a specific entity defined 
as concomitant existence of clinically relevant atheroscle-
rotic disease in at least two large vascular territories. 
Patients with lower extremity and carotid artery PAD 
have a high risk of associated coronary artery disease 
(CAD), therefore requiring interdisciplinary approach in 
diagnosis and treatment10. This article will primarily 
tackle atherosclerotic events in lower extremities. Lower 
extremity PAD can be asymptomatic or accompanied by 
symptoms such as intermittent claudication, atypical pain 
in legs, critical limb ischemia, and occasional acute limb 
ischemia11. Irrespective of the presence of symptoms, PAD 
is associated with a significantly higher risk of CVD mor-
bidity and mortality, thus posing a major public health 
problem12. Atherosclerosis is the most common cause of 
PAD, which makes it a primary therapeutic target13. The 
process of PAD diagnosis includes patient history data, 
clinical or physical examination, and subclinical identifi-
cation of peripheral atherosclerotic disease by use of non-
invasive diagnostic methods. The basic diagnostic test is 
determination of the ankle-brachial index (ABI) used not 
only to confirm the diagnosis but also to determine PAD 
severity. The values of ABI <0.9 are considered as patho-
logic, whereas ABI <0.5 indicates a high risk of amputa-
tion14. This can be followed by computed tomography angi-
ography (CTA) and digital subtraction angiography 
(DSA), which is currently employed when endovascular 
intervention is planned15. Contrast magnetic resonance 
angiography (MRA) has higher specificity than CTA and 
higher sensitivity than duplex US in detecting >50% ar-
terial stenosis, and is better tolerated by patients as com-
pared with contrast angiography.
Association of Peripheral Artery Disease 
and Coronary Disease
Patients with PAD are at a higher risk of subclinical 
coronary disease and cardiovascular events as compared 
with healthy control subjects16. Cardiovascular risk cor-
relates with symptom severity. Hospitalization for symp-
tomatic PAD is a potential marker of the disease severity 
and is associated with poorer outcomes17. Symptomatic 
PAD is associated with 70% greater risk of cardiovascu-
lar events and 80% greater risk of death as compared 
with PAD-free patients. The prevalence of myocardial 
infarction is 2.5-fold greater in patients with clinically 
significant PAD (defined as ABI <0.9) as compared with 
PAD-free patients18. Recent studies have revealed that 
local indicators of peripheral artery atherosclerosis other 
than ABI value, e.g., plaque echogenicity or femoral ar-
tery intima-media thickness (IMT), also are useful pa-
rameters in cardiovascular risk assessment19,20. The pres-
ence of PAD is frequently associated with advanced 
coronary disease, including involvement of the main cor-
onary trunk or polyvascular coronary disease quantified 
by a high SYNergy between percutaneous coronary inter-
vention with TAXus and cardiac surgery (SYNTAX) 
study result. The severity of PAD correlates with the 
cardiovascular disease development and complications. 
The mechanism underlying these observations most prob-
ably is multifactorial21. PAD patients having undergone 
chronic total occlusion percutaneous coronary interven-
tion (CTO PCI) had more comorbidities, more complex 
lesions, and poorer procedural success as compared with 
PAD-free patients22. The cross-talk of PAD, CAD and car-
diovascular events can be defined as clinical overlapping 
with the established atherosclerotic risk factors that pre-
dict development of both PAD and CAD. Among others, 
these risk factors include male sex, age, diabetes mellitus, 
smoking habit, hypertension, hyperlipidemia, and chron-
ic renal failure. In addition to the traditional risk factors, 
first-degree relatives of PAD patients are exposed to a 
higher risk of subsequent development of PAD and car-
diovascular events, thus emphasizing the hereditary na-
ture and multifactorial contribution to the disease on-
set23. Upon recognizing the clinical or subclinical 
manifestations of PAD, the effect of atherosclerotic dis-
ease can be alleviated by aggressive modification of the 
risk factors. The increasing rate of adverse cardiovascu-
lar events in PAD patients may in part be attributed to 
the less aggressive management of those risk factors. It 
is known that peripheral vascular disease is quite fre-
quently under-recognized and under-treated in these pa-
tients. Patients with concomitant PAD and CAD are pre-
scribed more sparing antiaggregating therapy, 
beta-blockers, angiotensin-converting enzyme (ACE) in-
hibitors and statins as compared to patients with coro-
nary disease alone. It has been demonstrated that higher 
statin doses and lower low-density lipoprotein cholesterol 
(LDL-C) levels are independently associated with better 
outcomes in these patients, suggesting the value of ther-
apy targeted to risk factors, particularly considering the 
lack of alternative treatment strategies24. It can be spec-
ulated that PAD actually is a peripheral manifestation of 
the already existing coronary disease, for which such 
preventive measures could prove useful. Besides the over-
lapping risk factors, PAD can independently trigger un-
favorable cardiovascular events. Phenotypic variations in 
the risk factor profiles have been observed between pa-
tients with peripheral and coronary disease. PAD pa-
tients tend to have higher triglyceride and high-density 
lipoprotein cholesterol (HDL-C) levels. In addition, PAD 
causes functional restrictions in exercise or in the activ-
ities known to be cardioprotective. Furthermore, PAD 
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patients are known to have abnormal peripheral vasodi-
lation and paradoxical vasoconstriction in response to the 
increased metabolic demands induced by stress25. This 
inadequate arterial vasodilation can lead to enhanced 
systemic load, thus reducing heart action and oxygen sup-
ply. This mechanism contributes to unfavorable cardio-
vascular outcomes. The higher prevalence of adverse 
cardiovascular events in PAD patients most likely results 
from a combination of overlapping direct and indirect 
causative factors associated with the development of PAD 
and its hemodynamic sequels. Inflammatory markers 
(C-reactive protein /CRP/, fibrinogen, interleukin-6, tu-
mor necrosis factor-α) have also been identified as one of 
the strongest predictors of cardiovascular risk in patients 
with PAD and coronary disease. A novel therapeutic goal 
will be identifying the triggers of inflammation in the 
development of atherosclerotic disease and modulation of 
inflammation in PAD and CAD.
Treatment of Peripheral Artery Disease
The aim of PAD management is to improve the patient 
quality of life, to increase walk distance, and to reduce 
the prevalence of fatal cardiovascular events26. PAD and 
CVD show overlapping conditions of similar yet separate 
basic pathophysiologic mechanisms. The severity of PAD 
correlates with cardiovascular outcomes. With the ever 
better and refined understanding of atherosclerotic dis-
ease, modulation of systemic inflammation will play ever 
more important role in upgrading therapeutic options for 
both diseases. Until then, the latest guidelines for PAD 
management are focused on aggressive modification of 
risk factors, smoking cessation, introducing antiaggrega-
tion therapy, hypolipemics, optimal glycemia and blood 
pressure regulation in PAD patients, with the highest 
level of recommendations addressing symptomatic pa-
tients, and walking exercise26. In patients with artery 
stenosis >80%, recommendations include organized exer-
cises to increase walk distance at least three times a week 
for at least 12 weeks in the form of 45- to 60-min training. 
According to the Evidence-based Practice Center System-
atic Review Protocol, the majority of studies report on the 
increase in walk distance to occur after 6 months to 2 
years of exercise. In addition, increasing walk distance is 
efficiently supported by medicamentous therapy for PAD, 
especially cilostazol and naftidrofuryl. Cilostazol im-
proves arterial blood flow to lower extremities via two 
mechanisms, i.e. by preventing thrombus formation and 
vasodilation. However, the main side effects of this agent 
are headache and diarrhea, while it is contraindicated in 
patients with heart failure. Naftidrofuryl reduces platelet 
and red blood cell aggregation, and according to a me-
ta-analysis of five studies, it is efficient in reducing pain 
and increasing walk distance by 26% as compared with 
placebo27. The use of ACE inhibitors and angiotensin re-
ceptor antagonists in patients with hypertension and 
PAD is associated with a decreased rate of major cardio-
vascular events and mortality, thus they should be the 
preferred treatment option28,29. In patients with mild to 
moderate limb ischemia, therapy with beta-blockers did 
not aggravate disease symptoms; however, caution is war-
ranted in patients with critical limb ischemia30. Anti-
platelet therapy is indicated for secondary prevention of 
cardiovascular events in patients with symptomatic PAD. 
Standard antiplatelet therapy for PAD includes use of 
monotherapy in all patients with carotid artery stenosis, 
irrespective of clinical symptoms and revascularization; 
monotherapy in case of symptomatic disease of lower ex-
tremity arteries, where clopidogrel is preferred over ace-
tylsalicylic acid; dual antiplatelet therapy for at least one 
month of percutaneous revascularization of lower extrem-
ities; and permanent oral anticoagulant therapy in com-
bination with antiplatelet therapy for at least one month 
of percutaneous revascularization in patients with PAD 
and atrial fibrillation and with CHA2DS2-VASc score ≥2 
or after implantation of mechanical cardiac valve31. After 
COMPASS study, antiplatelet monotherapy with acetyl-
salicylic acid in combination with low (vascular) dose of 
rivaroxaban, a direct oral anticoagulant (2.5 mg twice 
daily), is recommended for better cardiovascular and low-
er limb protection in PAD patients32,33. Results of the VO-
YAR PAD study published in March 2020 showed the use 
of the same (vascular) dose of rivaroxaban in combination 
with acetylsalicylic acid to be superior to acetylsalicylic 
acid monotherapy in PAD patients having undergone low-
er extremity revascularization, those with a significantly 
lower prevalence of composite outcome of acute limb isch-
emia, major amputation due to vascular causes, myocar-
dial infarction, ischemic stroke, or death from cardiovas-
cular causes. The incidence of thrombolysis in 
myocardial infarction (TIMI) major bleeding did not dif-
fer significantly between the groups. The incidence of 
major bleeding according to the International Society on 
Thrombosis and Hemostasis (ISTH) was significantly 
greater with a combination of rivaroxaban and acetylsal-
icylic acid than with acetylsalicylic acid alone34. In pa-
tients with symptomatic intermittent claudication, revas-
cularization was indicated after failure of optimal 
medicamentous therapy and exercise therapy. In this 
patient population, the aim of revascularization is to im-
prove their functional status and quality of life, and to 
prevent critical limb ischemia. Endovascular approach is 
recommended in patients with claudications that restrict 
their quality of life, with hemodynamically pronounced 
aortoiliac disease, primarily in case of femoropopliteal 
occlusion <25 cm, whereas surgical revascularization is 
the preferred option in others. Extremity amputation is 
the method of choice in patients with irreversible lower 
limb ischemia and in those with extensive necrosis or 
infected gangrene35. Critical limb ischemia is associated 
with 20% higher mortality and 50% greater risk of ex-
tremity amputation in patients not submitted to approach, 
tailored to each individual patient, including due control 
of atherosclerotic risk factors, revascularization, and re-
habilitation protocol. 
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Impact of COVID–19 on Peripheral Artery 
Disease
Morbidity and mortality associated with PAD in-
creased significantly during the COVID-19 pandemic37. 
Bellosta et al. observed an increased incidence of acute 
limb ischemia in patients with COVID-19 infections and 
an almost eightfold increase in total patients with acute 
limb ischemia during peak COVID-19 pandemic com-
pared to the same time period 201938. 
COVID-19 infection can cause severe alterations in 
coagulation mechanisms, leading some patients to pres-
ent severe acute arterial complications such as thrombo-
sis, as the only associated manifestation39. During the 
COVID-19 pandemic the organization of work of health 
institutions has significantly changed and   focused at-
tention on pandemic management. This has led to im-
portant changes in the treatment of patients without 
COVID-19 and resulted in heavier approach to care with 
delayed diagnosis and treatment. All  recommendations 
for treatment PAD stem from the time before the 
COVID-19 pandemic. The COVID-19 pandemic has had 
repercussions for patients with peripheral artery disease 
that range from increased amputations to payoffs in 
terms of efforts to keep patients out of hospitals while 
still complying to treatment recommendations. The real 
consequences of COVID-19 on treatment CVD will be 
estimated in the following years.
Conclusion
PAD is an important indicator of overall cardiovascular 
health due to its underlying pathophysiology – atherosclero-
sis. The prevalence of PAD is likely to increase steadily in 
the future due to the global aging of the population and the 
predominantly sedentary lifestyle, along with the expected 
universal increase in the major PAD risk factors such as 
smoking habit, diabetes mellitus, and hypertension.
The goal is to diagnose asymptomatic PAD as early as 
possible because it is a sign of systemic atherosclerosis. A 
strong correlation between symptomatic PAD and the sever-
ity of cardiovascular outcomes was confirmed. Therefore, it 
is of utmost importance to identify the population at risk, to 
influence the occurrence of the disease by appropriate pri-
mary prevention measures, and to modify risk factors by 
lifestyle modification and therapeutic measures available. 
The main goal of current therapy is better cardiovascular 
and lower limb protection in PAD patients. We believe that 
novel therapy will be focused on timely recognizing the trig-
gers of inflammation in atherosclerotic disease develop-
ment, along with modulation of inflammation in PAD and 
CAD. The COVID-19 pandemic also has had repercussions 
for patients with peripheral artery disease that range from 
increased amputations to payoffs in terms of efforts to keep 
patients out of hospitals while still complying to treatment 
recommendations. Further follow-up is still needed for the 
long-term outcomes of the COVID-19 pandemic on the 
treatment of CAD.
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BOLESTI KARDIOVASKULARNOG KONTINUUMA – PERIFERNA ARTERIJSKA BOLEST PREMA 
KORONARNOJ BOLESTI
S A Ž E T A K
Bolest perifernih arterija (PAD) okluzivna je bolest ekstremiteta koja se nekad dijagnosticirala i liječila kao izolira-
na bolest udova ili drugih dijelova tijela. U današnje vrijeme uloga PAD-a prevladava zahvaćeni ud; umjesto toga, kar-
diovaskularni sustav mora se promatrati u cjelini, pri čemu PAD ima prognostičku ulogu. Oko 200 milijuna ljudi 
pogođeno je PAD-om širom svijeta. Prevalencija PAD-a vjerojatno će se kontinuirano povećavati u budućnosti zbog 
globalnog starenja stanovništva i pretežno sjedilačkog načina života, zajedno s očekivanim sveopćim porastom glavnih 
čimbenika rizika od PAD-a kao što su navika pušenja, dijabetes melitus i hipertenzija. Pacijenti s PAD-om imaju veći 
rizik od koronarne bolesti i kardiovaskularnih događaja u usporedbi sa zdravim kontrolnim ispitanicima. Ozbiljnost 
PAD-a korelira s razvojem i komplikacijama kardiovaskularnih bolesti. U bolesnika s PAD-om perkutana koronarna 
intervencija zahtjevnija je, povezana s više komorbiditeta, složenijim lezijama i lošijim proceduralnim uspjehom u us-
poredbi s pacijentima bez PAD-a. Već godinu dana preporučuje se primjena antitrombocitne terapije acetilsalicilnom 
kiselinom u kombinaciji s niskom (vaskularnom) dozom izravnog oralnog antikoagulanta za zaštitu kardiovaskularnih 
i donjih udova kod bolesnika s PAD-om. U budućnosti očekujemo bolje razumijevanje aterosklerotske bolesti, jaču mod-
ulaciju sistemske upale i otkriće novih terapija. U međuvremenu je potrebno identificirati rizičnu populaciju i agresivno 
tretirati klasične čimbenike - kontrolu krvnog tlaka, glikemije i lipida s antitrombocitima i novu antikoagulantnu tera-
piju. Cilj je zaštititi ud i sačuvati kardiovaskularni kontinuum. Negativne posljedice COVID-19 na liječenje KVB proci-
jenit će se u sljedećim godinama.
